PMID: 11343737May 10, 2001Paper

Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial

Lancet
T MeuriceP Amouyel

Abstract

The DD genotype for the angiotensin-I converting enzyme (ACE I) deletion allele (D) polymorphism is a possible genetic risk factor for restenosis after coronary stent implantation. We aimed to establish whether or not blockade of ACE with high doses of ACE inhibitors could reduce this risk of angiographic restenosis. We characterised the ACE I/D polymorphism in 345 consecutive patients who were undergoing coronary stenting. 115 had the DD genotype. We assigned 91 of these 115 patients to quinapril 40 mg daily (n=46) or placebo (n=45). Treatment was started within 48 h after stent implantation and continued for 6 months. 79 patients complied with the protocol and underwent follow-up angiography after 6 months. Our primary endpoint of late loss in minimum lumen diameter (a quantitative index of restenosis) was significantly higher in the quinapril group than in the controls (mean 1.11 mm [SD 0.70] vs 0.76 mm [0.60]; p=0.018). Secondary endpoints also showed consistent trends towards increased angiographic restenosis in the treatment group. Contrary to our expectations, ACE inhibitor treatment did not reduce restenosis after coronary stent implantation in patients with DD genotype, but was associated with an exaggerated restenotic...Continue Reading

References

Nov 1, 1992·Pharmacology & Therapeutics·J M Hall
Jan 3, 1991·The New England Journal of Medicine·P W SerruysL Kappenberger
Jan 13, 1998·Journal of the American College of Cardiology·R KornowskiM B Leon

❮ Previous
Next ❯

Citations

May 9, 2007·Cardiovascular Drugs and Therapy·James P Tsikouris, Michael J Peeters
Apr 11, 2003·Current Treatment Options in Cardiovascular Medicine·Eric LaroseMartial G. Bourassa
Jul 3, 2007·Current Treatment Options in Cardiovascular Medicine·Agnieszka SlowikAndrzej Szczudlik
Aug 3, 2005·International Journal of Cardiology·L J WagenaarW H van Gilst
Jan 11, 2003·The American Journal of Cardiology·Flavio RibichiniEugenio Uslenghi
Oct 29, 2002·The American Journal of Medicine·Ernesto L Schiffrin
Feb 19, 2002·Journal of the American College of Surgeons·G Patrick Clagett
Aug 24, 2005·International Journal of Clinical Practice·R JaumdallyC Varma
Oct 26, 2005·Current Controlled Trials in Cardiovascular Medicine·Madlaina ScharplatzLucas M Bachmann
Apr 17, 2002·Circulation Journal : Official Journal of the Japanese Circulation Society·Kenji OkumuraTetsuo Hayakawa
Apr 2, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Tatsuo YamazakiSeibu Mochizuki
Aug 22, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yoshiyuki YamamotoRyoji Ozono
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Stefan Peters
Aug 27, 2003·Southern Medical Journal·John P Higgins
Dec 23, 2004·Journal of Cardiovascular Pharmacology·Bas LangeveldWiek H van Gilst
Feb 25, 2006·The Canadian Journal of Cardiology·Thierry CharronBradley H Strauss
May 8, 2007·International Journal of Cardiology·Hendrik C GroenewegenBart J G L de Smet
Sep 6, 2012·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Feroze NazneenMichael Thompson
Feb 3, 2005·International Journal of Cardiology·Stefan PetersK Westermann
Nov 6, 2003·The American Journal of Medicine·Vivek Rajagopal, Stanley G Rockson
Sep 19, 2009·Expert Opinion on Drug Metabolism & Toxicology·Arne Georg KiebackThorsten Reffelmann
Oct 2, 2003·Expert Opinion on Investigational Drugs·Jun R Chiong, Alan B Miller
Jul 2, 2005·Expert Opinion on Emerging Drugs·J Linde, B H Strauss
Jan 15, 2008·International Journal of Cardiology·Jin YokoyamaKen Okumura
Jan 13, 2009·Atherosclerosis·Heleen M M van BeusekomWillem J van der Giessen
Nov 3, 2005·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Flavio RibichiniWilliam Wijns
May 18, 2016·Therapeutic Advances in Cardiovascular Disease·Zhuang Xiao-DongDu Zhi-Min
Feb 4, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Philip Chan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.